Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pyridoxal Phosphate
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Details :
Product Name : MC-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : Pyridoxal Phosphate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyridoxal Phosphate
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : MC-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2023
Lead Product(s) : Pyridoxal Phosphate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable